Gerresheimer continues to invest in prefilled syringes

Date: 29 November 2010
Source: Gerresheimer AG
 A fourth production line for prefilled glass syringes is planned for the Bünde plant (Germany)  Investment total of approximately EUR 20 million  Completion in 2012 Gerresheimer AG, one of the world’s leading suppliers to the pharma and healthcare industry, is making further investments in the growth market for prefilled syringes.

The three existing production lines for RTF® syringes (Ready-To-Fill syringes) at the Bünde plant (Germany) are now to be supplemented by an additional, latest-generation line. Double-digit rates of annual growth are being recorded in the prefilled glass syringe market. Gerresheimer, the clear number two in the global market, is now stepping up its production capacity and investing around EUR 20 million in a fourth production line for prefilled syringes which will be completed in 2012. The new line will then add an annual capacity of up to 120 million syringes.

“We are a successful supplier of syringes to pharmaceutics customers around the world. Now we are investing in this fast-growing market again to consolidate our global market position further. The technical knowhow of our Syringe Competence Centre in Bünde makes it the ideal platform for further growth,” said Uwe Röhrhoff, CEO of Gerresheimer AG.

More information on prefilled syringes at: http://www.gerresheimer.com/produkte-services/pharma-healthcare/ tubular-glass/spritzensysteme.html

About Gerresheimer

Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors. Our Group has production operations at 40 sites in Europe, North and South America and Asia. It realizes sales of around one billion euros and has 9,500 employees. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.

See more news about: